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Medicalization, smoking and e-cigarettes: Evidence and implications 
 
ABSTRACT 
There is debate in the tobacco control literature about the value of a medical model in 
reducing smoking-related harm. The variety of medical treatments for smoking cessation has 
increased, health professionals are encouraged to use them to assist smoking cessation, and 
tobacco dependence is being described as a “chronic disease”. Some critics suggest that the 
medicalization of smoking undermines the tobacco industry's responsibility for the harms of 
smoking. Others worry that it will lead smokers to deny personal responsibility for cessation, 
create beliefs in “magic bullets” for smoking cessation, or erode smokers’ confidence in their 
ability to quit. We argue that the medicalization of smoking will have limited impact due to 
the emphasis on population-based interventions in tobacco control, the ambiguous place of 
nicotine amongst other drugs, and the modest efficacy of current pharmacotherapies. These 
factors, as well as lay understandings of smoking that emphasize willpower, personal choice 
and responsibility, have contributed to the limited success of medical approaches to smoking 
cessation. While the rapid uptake of e-cigarettes in some countries have provided an option 
for those who reject medical treatments for smoking cessation, current regulatory 
developments could limit the potential of e-cigarettes to provide non-therapeutic nicotine for 
those who currently smoke tobacco.    
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INTRODUCTION 
Some in the tobacco control field have argued that the increasing medicalization of smoking 
cessation could deter unassisted quit attempts1 or lead to a belief in “magic bullets” for 
tobacco dependence2. A broad critique of medicalization is that it “places excessive emphasis 
on the biological and individual determinants of disease at the expense of a more holistic 
perspective that emphasizes the social, cultural, and environmental contributions to disease 
and illness.’’3 This paper outlines the historical context in which smoking came to be 
described and treated as a medical problem; examines the extent to which smoking has 
become medicalized in high income countries; and identifies a number of factors that have 
limited the reach of a biomedical approach to reducing tobacco smoking. The paper 
concludes with a discussion about the potential of e-cigarettes to disentangle nicotine from 
therapeutic approaches to cessation, thereby creating a non-medical way to quit smoking that 
does not require nicotine abstinence.  
 
BIOMEDICAL DEFINITIONS OF TOBACCO DEPENDENCE: FROM “BAD 
HABIT” TO “NICOTINE ADDICTION”  
Medicalization occurs when a social issue is defined as a medical condition. This can occur at 
the conceptual, institutional or interactional level.4 The conceptual level refers to the 
application of a medical definition or label. Medicalization at the institutional level involves 
the uptake of medical definitions and models by key institutions, such as in treatment 
guidelines for health services. The interactional level involves communication between a 
healthcare provider and their patients. Examples include diagnosing a patient with a disorder, 
or prescribing medication. Medicalization is rarely complete, and may occur at one level but 
have little impact at another.4  
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Power differentials between groups are central to medicalization theory. Early work on 
medicalization emphasized the power of the medical profession (i.e., doctors/physicians) to 
transform social deviance into medical illness.5 More recent work describes the way that 
medicalization appears to be accelerating under the influence of the pharmaceutical and 
health insurance industries.6 Some believe that “technoscientific innovations” such as 
genomics and biotechnology have fundamentally transformed the medical arena in a process 
termed biomedicalization,6 although there is a debate about whether biomedicalization 
fundamentally departs from medicalization, or represents a shift of influence and power.7  
 
In tobacco control, medical definitions of tobacco smoking have become more prevalent over 
time, beginning with the labelling of smoking as an addiction. Early in the 20th century, 
tobacco use was seen as problematic by some, but it was not perceived as an inebriating drug 
like alcohol or opiates, so tobacco use was not categorized as a “disease” like other addictive 
drugs.8 While some pointed to features of smoking that signalled addiction,9 the term 
"addiction" was not widespread and addiction was not recognised as a factor in smoking in 
official government documents. As public awareness of the health risks of smoking increased 
in the 1950 and 60s, more smokers attempted to quit, leading to the observation that many 
smokers had difficulty in stopping. 
 
Nonetheless, it was not until 1988 that the US Surgeon General concluded that tobacco 
smoking was addictive, primarily because of the reinforcing effects of nicotine. Cigarettes 
were redefined as a “delivery device” for nicotine, an addictive drug “in the same sense as … 
heroin and cocaine.”10 The move from describing smoking as “habituation” in the 1964 report 
to “nicotine addiction” in 1988 was influenced by neuroscience insights about how nicotine 
worked in the brain and evidence that nicotine replacement therapy (NRT) reduced cravings 
for cigarettes.11   
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 Diagnostic criteria was another domain in which medical labels began to be applied to 
smoking. While the tobacco industry claimed that it would be “ridiculous” to label a common 
everyday behaviour as a mental disorder,12 the arbiters of the DSM included “tobacco 
dependence” as a diagnostic category in the DSM-III. The 1987 revision renamed "tobacco 
dependence" as “nicotine dependence”, a label retained in DSM-IV.13 The diagnostic criteria 
for nicotine dependence were based on those for other drugs: tolerance, withdrawal 
symptoms, compulsive use, and use despite negative consequences. In the DSM-5, "nicotine 
dependence" was renamed “tobacco use disorder.” Very similar diagnostic criteria were 
applied with dependence diagnosed along a continuum of severity, from mild, moderate to 
severe dependence.  
 
The DSM-5 has been criticized for being more “expansive” than previous versions as all 
tobacco users can now be diagnosed with tobacco use disorder.12 Once critic noted the 
pharmaceutical industry's influence in redefining smoking as a psychiatric disorder which 
implies the need for medical, specifically pharmaceutical, treatment and argued that, “the 
psychiatric diagnosis of tobacco use disorder is more about the current social, political, and 
economic context of US medical and public health approaches to cigarettes than a valid 
description of a disease state.”12 
 
PHARMACOTHERAPY FOR SMOKING CESSATION AND THE ROLE OF THE 
HEALTH PROFESSIONAL 
Another key component of medicalization is the availability and promotion of medical 
treatments, such as pharmacotherapies for smoking cessation. NRT, in the form of gum, was 
first developed in the 1960s to reduce cravings for cigarettes when quitting, and prevent 
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relapse. Elam has written a comprehensive history of the development of NRT, including 
differences between countries.11 He describes “two competing scripts” about NRT, with 
debate occurring over whether NRT should be marketed as an alternative and safer way of 
using nicotine (a harm reduction approach) or solely as a medicine for smoking cessation (a 
medical approach)11. The latter came to dominate after clinical trials demonstrated NRT's 
efficacy in smoking cessation.14 15  
 
NRT is now available in multiple forms that vary in strength and speed of nicotine delivery. 
While initially available only via prescription, most forms of NRT are now available over-
the-counter in pharmacies and general retailers in many countries. The World Health 
Organization has added NRT to the Model List of Essential Medicines16 to encourage 
governments to provide NRT at low cost. Two non-nicotine prescription-only medications for 
smoking cessation are also widely available:  bupropion and varenicline. Both medicines are 
supported by clinical trial data, with varenicline demonstrating greater efficacy than 
bupropion or nicotine patches.17 18 Other potential smoking cessation medicines have been or 
are currently being investigated.19  
  
The use of smoking cessation pharmacotherapies has increased steadily since their 
introduction. In Australia, the use of cessation pharmacotherapy in a quit attempt in the 
previous year increased from 32% in 2002 to 52% in 2008.20 Similarly, in the UK, 53.6% of 
those who had quit in the previous year had used a cessation aid in 201021 However, there is 
poor treatment adherence, with many users prematurely discontinuing use.22-24 
 
The widespread use of pharmacotherapy contrasts with low uptake of behavioural support for 
smoking cessation, despite evidence that the most effective way to quit smoking is to use 
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both.14 Research in numerous countries shows low use of telephone support services for 
quitting.20 25 26  A 2011 UK report found that 54% of smokers who had made a quit attempt in 
the last year had used pharmacotherapy, but only 5.5% had attended cessation clinics which 
provide comprehensive support.21 Poor adherence to NRT in the community setting and low 
use of behavioural support has led to arguments that a medical approach to smoking may not 
be the optimal way to deal with the tobacco epidemic.1 
 
SMOKING AS A CHRONIC DISEASE  
Tobacco treatment guidelines in the USA, Australia, and the UK recommend that health 
professionals identify smokers, provide brief smoking cessation advice and prescribe 
pharmacotherapy.27-29 Some authors have recently recommended that health professionals 
should provide cessation treatment to all their smoking patients, regardless of their desire or 
“readiness” to quit.29-31 These authors argue that smoking should be treated as a “chronic 
disease” because smokers’ propensity to relapse makes smoking like hypertension, diabetes, 
or high cholesterol. The US Public Health Services Guidelines go further, stating that 
“Tobacco dependence is a chronic disease that often requires repeated intervention and 
multiple attempts to quit.”27 Tobacco smoking is increasingly portrayed not only as a risk 
factor for disease, but as a disease in itself.32  
 
Animal research and human neuroimaging studies that have that identified the neurochemical 
changes in the brain related to prolonged use of cocaine and heroin have encouraged the use 
of the "disease" label for smoking.33 34 The same approach was later applied to nicotine 
dependence. The concept that addiction is a disease is not new, but the idea that it has a 
specific neurobiological basis that can be pinpointed in the brains of smokers, allowing 
targeted drug treatment, is a more recent development. Older models of addiction framed 
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drug dependence as a disease of the will.35 Smoking is now described as a “chronic brain 
disorder.”36 
 
Proponents of this idea argue that a focus on biological factors will reduce moral judgements 
about addicted individuals, enable more humane public policy responses to addiction, and 
lead to improved treatment of addiction.37 A number of novel neurobiological treatments for 
smoking cessation have been developed or proposed, such as transcranial magnetic 
stimulation. This non-invasive procedure involves placing a magnetic device near the surface 
of the skull to stimulate neurons in targeted areas of the brain. Some studies suggest that this 
treatment may reduce cravings for cigarettes in the short-term38 39 but there is little evidence 
of long-term efficacy. Brain scans and pharmacogenetics may also be used in the future to 
identify those at risk of relapse to smoking and to match individuals to the most effective 
interventions.40-42 
 
CRITIQUES OF THE BIOMEDICALIZATION OF TOBACCO SMOKING 
While proponents of the medical approach to smoking are optimistic about its potential to 
produce better cessation aids, opponents are concerned about potential negative impacts of 
viewing and treating tobacco dependence as a disease. Despite the effectiveness of 
pharmacotherapy for smoking cessation in clinical trials, there are criticisms of the way these 
pharmaceutical aids are promoted.1 Critics point out that most smokers who use cessation 
pharmacotherapy fail to quit and that most clinical trials demonstrating the effectiveness of 
pharmacotherapies for smoking cessation are sponsored by pharmaceutical manufacturers.1 43 
Advocates of a medical model of smoking counter that even though these interventions only 
succeed in a minority of smokers, these treatments are cost-effective when compared to other 
health interventions.44 Some have argued that more smokers should be encouraged to use 
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them: “If there is a major failing in the UK approach, it is not that it has medicalized 
smoking, but that it has not done so enough.”45 
 
Critics of a biomedical model of smoking also argue that it neglects the fact that most 
smokers quit unaided, and may unwittingly make quitting seem more difficult than it is by 
eroding self-efficacy and agency.1 46 A focus on the addicted smoker’s brain, it is argued, 
could lead to: a diminution of the role of choice in public understandings of smoking; a 
neglect of structural and social factors that sustain smoking; and the potential for 
discrimination based on the neuromolecular status of individuals.3 A shift in emphasis from 
the cigarette to the smoker may also deflect attention from the role of the tobacco industry 
and its dangerous products. The tobacco industry were strong supporters of genetic research 
on addiction as a strategy to deflect blame for the health consequences of smoking from the 
cigarette to the “genetic constitution” of the smoker.47 A focus on the treatment of individuals 
may reduce the emphasis on broader, effective population based measures, such as increasing 
tobacco taxes and banning smoking in public spaces.48 
 
Medicalized understandings of addiction may also increase the stigma directed towards 
addicted individuals.49 50 Elam51 argues that brain-based explanations of smoking are 
responsible for “remoralizing” addiction, by portraying drug users as “brain hostages” who 
have lost control of themselves. At the same time, drug users are encouraged to take 
responsibility for protecting their brains and working to achieve a healthy state. Constant 
vigilance is required to “avoid being terrorized by our own neural circuitry gone awry.”51 
These criticisms of the medicalization of addiction closely align with the “darker sides” of 
medicalization described by Conrad and Schneider4 namely, the individualisation of social 
problems and the dislocation of individual responsibility.  
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 FACTORS LIMITING THE BIOMEDICALIZATION OF SMOKING  
There are a number of factors that are likely to limit the influence of a medical approach to 
smoking. Firstly, the tobacco control field emerged from epidemiology and public health.8 
Consequently, a medical approach has not displaced the population-based measures that 
remain central to the field’s research and policy advocacy. The WHO Framework Convention 
on Tobacco Control has a strong emphasis on population-based measures, with only one 
article on treatment for smoking cessation.52 Because many of the countries with increasing 
smoking prevalence have limited resources, an emphasis on cost-effective population-level 
interventions is vital. For countries in the early stages of the tobacco epidemic, the 
widespread treatment of individual smokers with pharmacotherapy is unlikely to be 
financially viable,1 although some have advocated for NRT as a cost-effective medication 
even in low-income countries.53 
 
A second factor limiting the biomedicalization of smoking is nicotine’s ambiguous place 
among other drugs.54 Nicotine has only mild psychoactive effects, and regular smokers do not 
become intoxicated. Smoking does not usually adversely affect an individual’s ability to 
function in everyday life or cause the social problems associated with other substance use. 
The adverse health effects often only emerge after decades of smoking. The intensity of 
medical treatment for addiction to alcohol or illicit drugs usually differs from that offered for 
nicotine. Treatment for other drugs often involves supervised detoxification, extended 
rehabilitation programs, or long-term substitution programs (e.g., methadone maintenance 
therapy for opioid dependence). It is very rare for smokers to receive inpatient care solely for 
their smoking, although there are exceptions.55 
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Many healthcare practitioners are unenthusiastic about a medical approach to smoking 
cessation. Despite the clinical recommendations described above, surveys in a number of 
countries show that most smokers are not offered assistance to quit by their physicians.20 21 25 
Smokers also appear resistant to using cessation aids or seeking professional assistance to 
quit. Many do not believe that NRT is effective for smoking cessation,56-58 or reducing 
cigarette cravings.59 Research with former smokers found that those who quit unassisted 
prioritised “lay knowledge” based on their own experiences and that of family and friends, 
over medical professionals’ advice on cessation treatment efficacy.60 While some clinicians 
see negative perceptions of NRT as misperceptions that should be corrected,57 59 they may be 
well based in the past experiences of many smokers who have failed to quit despite using 
pharmacotherapies. More research is required on how medical practitioners judge the efficacy 
of cessation pharmacotherapies, and how this may be influenced by the efficacy of other 
routinely prescribed medications.  
 
Many smokers are also concerned about the health risks of cessation pharmacotherapies. 
Smokers mistakenly believe that nicotine causes cancer,57 61-63 probably because of the close 
association between nicotine, cigarettes and the health harms of smoking.57 It may be difficult 
for people to understand that the harmful effects of cigarette smoking are much reduced when 
they obtain their nicotine in the form of NRT.57 61-63 Furthermore, some in public health have 
highlighted concerns about nicotine’s safety for long-term use in opposing the long term use 
of “cleaner” forms of nicotine, such as snus and e-cigarettes, as substitutes for cigarettes.64  
This is despite the fact that any harm caused by long-term nicotine use is likely to be minimal 
compared to the severe health risks of smoking cigarettes.65 Research conducted by the FDA 
on public opinion shows an increase over time in the belief that nicotine causes cancer.66 
Concerns about health risks are even more pronounced in relation to prescription 
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pharmacotherapies for smoking cessation. Smokers commonly believe that these have serious 
and life-threatening side effects,59 67 while ignoring the substantial risk of dying from 
continuing to smoke. 
 
Lastly, qualitative studies report that willpower and personal responsibility are key terms in 
smokers’ discourses about smoking and cessation.59 60 68 69 Assisted cessation conflicts with 
smokers’ conceptualisations of quitting that emphasize the importance of internal strength 
and willpower. Smokers often described smoking as having a behavioural or psychological 
aspect that cessation medications do not address.59 70 71 The key finding in these studies is that 
smokers believe that the physiological aspect of their addiction only partly explains why they 
continue to smoke. This finding is also supported by survey research. For example, a survey 
of current smokers’ found low levels of agreement that an inability to quit was caused by 
biological factors (21%), or that smoking was a “disease” (10%).72 This suggests that 
biomedical conceptualisations of smoking do not strongly align with the way that smokers 
understand their own smoking.  
 
E-CIGARETTES AND THE ROLE OF NICOTINE ADDICTION IN THE TOBACCO 
“ENDGAME”  
E-cigarettes have been described as a “disruptive technology” which has the potential to 
make cigarettes obsolete.73  They are controversial because opponents fear that the hand-to-
mouth action and exhalation of a visible 'vapour' could re-normalise smoking. Critics of e-
cigarettes stress their unknown long-term health risks and their potential role as a gateway 
into smoking for young people.74 As a non-therapeutic product, e-cigarettes present an 
“ideological challenge” to the dichotomization of nicotine into the “bad” form sold by 
tobacco companies and the “good” form sold as medicines by pharmaceutical companies.75 
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E-cigarettes provide a way to consume nicotine for non-therapeutic purposes, without 
incurring the harms caused by smoking tobacco. As such they occupy an ambiguous product 
category that is neither a tobacco product nor a medical aid for cessation.76 E-cigarettes could 
lead to a future in which nicotine becomes “disarmed” 11, and dissociated from both tobacco 
and medicines. Thus, e-cigarettes could lead to the de-medicalization of non-tobacco nicotine 
products by making recreational nicotine use much safer and more socially acceptable.  
 
Alternatively, e-cigarettes could be incorporated into medical models of smoking cessation. 
A medical or treatment-focused approach has generally been more open to using nicotine 
substitution for harm reduction. In the UK, e-cigarettes are largely viewed as an opportunity 
to help existing smokers quit. While the MHRA (UK medicines regulator) attempted to 
regulate all e-cigarettes as medical products, a "dual track" regulatory model was ultimately 
adopted allowing manufacturers to choose either the medicines licensing route or compliance 
with the European Union's Tobacco Products Directive. Only one e-cigarette has gained 
MHRA approval, but it is yet to be released to market. Nevertheless, e-cigarettes are being 
incorporated into the medical model of smoking cessation in the UK, with smoking cessation 
clinics encouraged to be “open to e-cigarette use in people keen to try them to help them 
quit”. Specific recommendations in this regard have been disseminated 77.   
 
In the USA, the FDA also originally moved to regulate e-cigarettes as therapeutic devices 
subject to the same stringent regulations as are applied to medicines. The vaping industry 
opposed this on the grounds that it would make it prohibitively expensive to obtain approval 
for their devices for all but the most well-resourced companies, such as those owned by 
tobacco and pharmaceutical companies. This argument is supported by the fact that the e-
cigarette so far to gain medicines licensing is marketed by a wholly-owned subsidiary of a 
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tobacco company.78 The FDA has now proposed to regulate e-cigarettes as tobacco 
products79, although this proposal is also being legally challenged.80 
 
The lack of commercial interest in gaining medicines approval for e-cigarettes has meant that 
countries that have restricted the sale of non-tobacco nicotine products to a medicines 
framework have had to decide between continuing what is effectively prohibition on nicotine-
containing e-cigarettes, or amending their regulations to permit a legal market in non-
therapeutic nicotine products. Recent announcements by the New Zealand and Canadian 
governments suggest they are taking the latter option.81 82 A rescheduling application has also 
been submitted to the Australian Therapeutic Goods Administration that could pave the way 
for nicotine vaping solutions to be sold as a non-therapeutic product, similar to smoked 
tobacco.83 
 
It might be assumed that regulating e-cigarettes as a consumer product will make them more 
appealing than NRT to those who reject adopting a sick role in relation to their smoking.  
However, in England, the rise in vaping appears to have reduced smoking by increasing the 
success rate of quit attempts rather than increasing the number of smokers making a quit 
attempt.84 E-cigarettes have indeed displaced NRT85 just as varenicline has displaced 
bupropion and NRT in the US.86 These findings suggest that major population impact of e-
cigarettes so far has been to increase the effectiveness of cessation compared to NRT,87 rather 
than by encouraging a broader range of smokers to quit smoking (e.g. non-treatment seekers). 
Indeed, a significant proportion of vapers report that they have previously used medicinal 
cessation aids unsuccessfully.88 
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Research with Australian e-cigarette users show that many are strongly opposed to regulating 
e-cigarettes as medicinal products.88 However, the most common reason for using e-
cigarettes reported by vapers is ‘to quit smoking',89 suggesting that many vapers have 
primarily used e-cigarettes as a type of quitting tool, albeit an unapproved one. To appeal to a 
wider range of smokers, e-cigarettes may need to become widely accepted as a superior 
nicotine product, rather than being perceived as a less harmful ersatz cigarette or a cessation 
device. Clearly, for the majority of smokers, this is yet to occur and may require both 
technological advances to improve nicotine delivery and a shift in public attitudes towards 
nicotine. However, if e-cigarettes continue to improve and become a superior nicotine 
delivery device relative to cigarettes then this could increase concerns about their 
addictiveness and use by non-smokers. Further regulation of tobacco cigarettes to make them 
less attractive compared to e-cigarettes, such as by increasing cost, reducing nicotine content, 
and/or prohibiting flavours and other additives, could help improve the relative attractiveness 
of e-cigarettes as an alternative nicotine product. Competing ideas about the future role of 
nicotine in tobacco control90-92 are contributing to strong debates about the optimal regulatory 
approach for these products in many counties.  
 
CONCLUSION 
The strongest form of medicalization portrays smoking as a “chronic brain disorder” in which 
individuals lose control of their behaviour and need medication to treat their “relapsing 
disease”. This view has prompted research into increasingly sophisticated biotechnological 
strategies for treating smoking, such as transcranial magnetic stimulation, pharmocogenetics, 
and brain scans. While this approach has concerned some commentators, we have argued that 
a number of factors make it unlikely that a medical model will become dominant in tobacco 
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control. We agree with others who describe the medicalization of smoking as “partial and 
fragmented.”93 
 
The medical definitions of smoking adopted by some influential institutions are not reflected 
in the way that smokers understand their smoking, and has not affected interactions between 
doctors and their smoking patients. Enthusiasm for a biomedical model of smoking should be 
tempered by the importance that smokers still place on the roles of willpower and choice, and 
the continued success of population level strategies in tobacco control. While a medical 
approach to smoking cessation will continue to play a role in reducing tobacco-related 
disease, it is unlikely to ever become the dominant approach.    
 
The regulatory decisions that many countries are currently making about e-cigarettes will 
shape their influence on the medicalization of smoking. The regulation and promotion of e-
cigarettes as therapeutic devices could limit the attractiveness of e-cigarettes to smokers who 
do not see their smoking as a medical problem in need of “treatment.” The UK approach, 
where e-cigarettes are regulated as consumer products, but also incorporated into cessation 
treatment by health professionals is a promising model. However, increasing the appeal of 
vaping as a substitute for smoking for non-treatment seeking smokers is a challenge that will 
need to be overcome if public health is to put this technology "to full use".94 While the future 
role of e-cigarettes remains unclear, they are likely to have implications for tobacco control 
policy, how nicotine is understood by the public, and the role played by health professionals 
in smoking cessation.  
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